Blood transfusions for treating acute chest syndrome in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 1, 2020, Pages

  Dolatkhah, Roya ^a   Dastgiri, Saeed ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN S;

ACUTE CHEST SYNDROME; ARTICLE; ASSISTED VENTILATION; BLOOD TRANSFUSION; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CLINICAL PRACTICE; ELECTRONIC MEDICAL RECORD; ERYTHROCYTE CONCENTRATE; EXCHANGE BLOOD TRANSFUSION; FEVER; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; LENGTH OF STAY; LUNG FUNCTION TEST; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT SATISFACTION; PRIORITY JOURNAL; PULSE OXIMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKLE CELL ANEMIA; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT DURATION; CHILD; COMPLICATION; META ANALYSIS; TREATMENT OUTCOME;

ACUTE CHEST SYNDROME; ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; CHILD; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85077941378     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007843.pub4     Document Type: Article

References (135)

1. Miller ST, Kim HY, Weiner DL, Wager CG, Gallagher D, Styles LA, et al. Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion 2013;53(4):704-9. [CFGD Register: SC224c; 5500100000011225]x-wiley/crsRef/2843544
2. NCT00951808. Preventing Acute Chest Syndrome by Transfusion Feasibility Study (PROACTIVE). https://clinicaltrials.gov/ct2/show/NCT00951808 (accessed 03 February 2016). x-wiley/crsRef/2843545
3. Styles L, Greene Wager C, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, et al. Refining the predictive value of secretory phospholipase A2 in sickle cell disease patients with acute chest syndrome. Proceedings of the 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California. 2011. [Abstract No.: 846; CFGD Register: SC224a; 5500100000010732]x-wiley/crsRef/4242074
4. Styles L, Wager CG, Labotka RJ, Smith-Whitley K, Thompson AA, Lane PA, et al. Refining the value of secretory phospholipase A2 as a predictor of acute chest syndrome in sickle cell disease: results of a feasibility study (PROACTIVE). British Journal of Haematology 2012;157(5):627-36. [CFGD Register: SC224b; 5500100000010598]x-wiley/crsRef/2843547
5. Doluee MT, Kakhki BR, Mir HH, Fateminayyeri M, Madanitorbati F, Hosseini S, et al. Pain relief in the sickle-cell crisis: intravenous morphine versus ketorolac; a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal 2019;21(4):e83614. x-wiley/crsRef/12645212
6. Heath LE, Heeney MM, Hoppe CC, Adjei S, Agbenyega T, Badr M, et al. Successful utilization of an electronic pain diary in a multinational phase 3. Clinical Trials 2017;14(6):563-71. [CFGD Register: SC298j]x-wiley/crsRef/12645214
7. Heeney M, Hoppe C, Abboud M, Inusa B, Kanter J, Ogutu B, et al. Determining effects of platelet inhibition on vaso-occlusive events (DOVE) trial: a double-blind, placebo-controlled, study of prasugrel in paediatric patients with sickle cell anaemia. Haematologica 2016;101 Suppl 1:136-7. [CFGD Register: SC298b]x-wiley/crsRef/12645215
8. Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. New England Journal of Medicine 2016;374(7):625-35. [SC298a]x-wiley/crsRef/12645216
9. Heeney MM, Hoppe CC, Rees DC. Prasugrel for sickle cell vaso-occlusive events. New England Journal of Medicine 2016;375(2):185-6. [CFGD REgister: SC298h]x-wiley/crsRef/12645217
10. Hoppe CC, Jakubowski JA, Foster WM, Heath LE, Pillai S, Pallav B. Candidate Gene Associations with Vaso-Occlusive Crisis in Children with Sickle Cell Anemia Enrolled in the Multinational DOVE Trial. Blood 2017;130(Supplement 1):962. [CFGD Register: SC298k]x-wiley/crsRef/12645218
11. Inusa B, Colombatti R, Rees DC, Heeney MM, Hoppe CC, Ogutu B, et al. Geographic differences in phenotype and treatment of children with sickle cell anaemia from the multinational DOVE study. Blood. Conference: 58th annual meeting of the American society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206 2016;128(22):3653. [CFGD Register: SC298e]x-wiley/crsRef/12645219
12. Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, et al. Point of care platelet reactivity testing and dose-titration in a double-blind study of prasugrel in children with sickle cell anaemia. Haematologica 2016;101 Suppl 1:585. [Abstract no.: E1412; CFGD Register: SC298c]x-wiley/crsRef/12645220
13. Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, et al. Real time dose adjustment utilizing point of care platelet reactivity testing in a double blind study of prasugrel in children with sickle cell anaemia (SCA). Thrombosis and Haemostasis 2016;14 Suppl 1:113. [Abstract No.: PP19; SC298d]x-wiley/crsRef/12645221
14. Jakubowski JA, Hoppe CC, Zhou C, Smith BE, Brown PB, Heath LE, et al. Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis 2017;117(3):580-8. [CFGD Register: SC298i]x-wiley/crsRef/12645222
15. Kanter J, Heath LE, Zhou C, Agbenyega T, Colombatti R, Dampier C, et al. Regional-and age-related differences in pain in children with sickle cell anemia: results from the multinational DOVE study. Blood 2016;128(22):3654. [CFGD Register: SC298f]x-wiley/crsRef/12645223
16. Beverung LM, Strouse JJ, Hulbert ML, Neville K, Liem RI, Inusa B, et al. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. American Journal of Hematology 2015;90(2):139-43. x-wiley/crsRef/12645225
17. Bhatnagar P, Casella EB, Arking DE, Casella JF. Genome-wide association for silent cerebral infarction (SCI) in sickle cell disease: the silent infarct transfusion trial (SIT) cohort. Blood 2009;114(22):2563. x-wiley/crsRef/12645226
18. Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, Arking DE, et al. Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. Journal of Human Genetics 2011;56(4):316-23. x-wiley/crsRef/12645227
19. Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, Arking DE, et al. Genome-wide association study identifies genetic variants influencing F-cell levels in sickle-cell patients. Journal of Human Genetics 2011;56(4):316-23. Supplementary information. http://www.nature.com/jhg/journal/v56/n4/suppinfo/jhg201112s1.html. x-wiley/crsRef/12645228
20. Bundy DG, Richardson TE, Hall M, Raphael JL, Brousseau DC, Arnold SD, et al. Association of guideline-adherent antibiotic treatment With readmission of children with sickle cell disease hospitalized with acute chest syndrome. JAMA Pediatrics 2017;171(11):1090-99. x-wiley/crsRef/12645229
21. Casella JF, King AA, Barton B, White DA, Noetzel MJ, Ichord RN, et al. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatric Hematology & Oncology 2010;27(2):69-89. x-wiley/crsRef/12645230
22. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine 2014;371(8):699-710. x-wiley/crsRef/12645231
23. DeBaun MR, Sarnaik SA, Rodeghier MJ, Minniti CP, Howard TH, Iyer RV, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012;119(16):3684-90. x-wiley/crsRef/12645232
24. Eigbire-Molen O, Darbari DS, Ponisio MR, Milchenko MV, Rodeghier MJ, Casella JF, et al. Progressive loss of brain volume in children with sickle cell anemia: a report from the silent cerebral infarct transfusion trial cohort. Blood 2015;126(23):546. x-wiley/crsRef/12645233
25. Gay JC, McCavit T, Bundy D, King A, Lehman HP, Strouse JJ, et al. Cost-effectiveness of blood transfusions versus observation for silent cerebral infarcts from the silent cerebral infarct trial. Blood 2016;128(22):3655. x-wiley/crsRef/12645234
26. Glassberg JA, Wang J, Cohen R, Richardson LD, DeBaun MR. Risk factors for increased ED utilization in a multinational cohort of children with sickle cell disease. Academic Emergency Medicine 2012;19(6):664-72. x-wiley/crsRef/12645235
27. ISRCTN52713285. Silent Cerebral Infarct Multi-Center Clinical Trial. www.isrctn.com/ISRCTN52713285 24 August 2004. [Protocol/ serial number: U01NS42804]x-wiley/crsRef/12645236
28. Kawadler JM, Clark CA, McKinstry RC, Kirkham FJ. Brain atrophy in paediatric sickle cell anaemia: findings from the silent infarct transfusion (SIT) trial. British Journal of Haematology 2016; Vol. Apr 7 [Epub ahead of print]. [DOI: 10.1111/bjh.14039]x-wiley/crsRef/12645237
29. King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, et al. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. American Journal of Hematology 2014;89(10):188-92. [CFGD Register: SC184p]x-wiley/crsRef/12645238
30. King, AA, Strouse JJ, Rodeghier MJ, Compas BE, Casella JF, McKinstry RC, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. American Journal of Hematology 2014;89(2):162-7. x-wiley/crsRef/12645239
31. Kirkham FJ, Darekar E, Kija R, Bhadresha R, McSwiggan J, Cox SE, et al. Brain T2-weighted signal intensity ratio in children with sickle cell disease with and without stroke. European Journal of Paediatric Neurology 2011;15 Suppl 1:S60. [Abstract no: P07.3]x-wiley/crsRef/12645240
32. Land V, Heijboer H, Fijnvandraat K, DeBaun MR, Casella JF. Transfusions for silent cerebral infarcts in sickle cell anemia. New England Journal of Medicine 2014;371(19):1841-2. x-wiley/crsRef/12645241
33. Liem RI, Liu J, Gordon MO, Vendt BA, McKinstry RC 3rd, Kraut MA, et al. Reproducibility of detecting silent cerebral infarcts in pediatric sickle cell anemia. Journal of Child Neurology 2014;29(12):1685-91. x-wiley/crsRef/12645242
34. NCT00072761. Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT). clinicaltrials.gov/show/NCT00072761 Date first received: 10 November 2003. x-wiley/crsRef/12645243
35. Ogunsile FJ, DeBaun MR, Currie K, Rodeghier MJ. Parvovirus B19 infection associated with silent cerebral infarcts: a secondary analysis of the silent cerebral infarct trial cohort. Blood 2015;126(23):3410. x-wiley/crsRef/12645244
36. Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, et al. Acute silent cerebral ischemia occurs more frequently than silent cerebral infarction in children with sickle cell anemia. Blood 2010;116(21):268. x-wiley/crsRef/12645245
37. Roberts DO, Covert B, Rodeghier M, Parmar N, DeBaun MR, Thompson AA, et al. Randomization is not associated with socio-economic and demographic factors in a multi-center clinical trial of children with sickle cell anemia. Pediatric Blood & Cancer 2014;61(9):1529-35. x-wiley/crsRef/12645246
38. Thangarajh M, Yang G, Fuchs D, Ponisio MR, McKinstry RC, Jaju A, et al. Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia. British Journal of Haematology 2012;159(3):352-9. x-wiley/crsRef/12645247
39. Vendt BA, McKinstry RC, Ball WS, Kraut MA, Prior FW, Barton B, et al. Silent cerebral infarct transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain. Journal of Digital Imaging 2009;22(3):326-43. x-wiley/crsRef/12645248
40. Wolf RB, Saville BR, Roberts DO, Fissell RB, Kassim AA, Airewele G, et al. Factors associated with growth and blood pressure patterns in children with sickle cell anemia: Silent Cerebral Infarct Multi-Center Clinical Trial cohort. American Journal of Hematology 2015;90(1):2-7. x-wiley/crsRef/12645249
41. van der Land V, Heijboer H, Fijnvandraat K, DeBaun MR, Casella JF. Transfusions for silent cerebral infarcts in sickle cell anemia. New England journal of medicine 2014;371(19):1841-2. x-wiley/crsRef/12645250
42. Abboud M, Cure J, Gallagher D, Berman B, Hsu L, Wang W, et al. Magnetic resonance angiography (MRA) in children with abnormal transcranial doppler (TCD) velocities in the STOP study. Blood 1999;94(10 Suppl 1):645a. x-wiley/crsRef/12645252
43. Abboud MR, Cure J, Gallagher D, Berman B, Hsu L, Wang W, et al. Magnetic resonance angiography in children with abnormal TCD in the STOP study. 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:49. x-wiley/crsRef/12645253
44. Abboud MR, Cure J, Granger S, Gallagher D, Hsu L, Wang W, et al. Magnetic resonance angiography in children with sickle cell disease and abnormal transcranial Doppler ultrasonography findings enrolled in the STOP study. Blood 2004;103(7):2822-6. x-wiley/crsRef/12645254
45. Adamkiewicz T, Abboud M, Barredo J, Cavalier ME, Peterson J, Rackoff B, et al. Serum Ferritin in children with SCD on chronic transfusion: correlation with serum alanine aminotransferase and liver iron (STOP/STOP II liver iron ancillary study). 35th Annivesary Convention of the National Sickle Celll Disease Program and the Sickle Cell Disease Association of America; 2007 Sep 17-22; Washington DC, USA. 2007:316. x-wiley/crsRef/12645255
46. Adamkiewicz T, Abboud MR, Barredo JC, Kirby-Allen M, Alvarez OA, Casella JF, et al. Serum ferritin in children with sickle cell disease on chronic transfusion: measure of iron overload or end organ injury? STOP/ STOP II liver iron ancillary study. Blood. 2006; Vol. 108, issue 11. [Abstract no: 791]x-wiley/crsRef/12645256
47. Adamkiewicz TV, Abboud MR, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 2009;114(21):4632-8. x-wiley/crsRef/12645257
48. Adams R, Fullerton H, Kwiatkowski J, Voeks J. Development of high risk TCD in sickle cell disease. Stroke; a journal of cerebral circulation 2015;46(Suppl 1):Abstract no: 17. x-wiley/crsRef/12645258
49. Adams RJ. Lessons from the stroke prevention trial in sickle cell anemia (STOP) study. Journal of Child Neurology 2000;15(5):344-9. [NCT00000592: Stroke Prevention in Sickle Cell Anemia (STOP 1)]x-wiley/crsRef/12645274
50. Adams RJ, Brambilla DJ. Stroke prevention trial in sickle cell anemia: STOP. 21st Annual Meeting of the National Sickle Cell Disease Program. 1996:19. x-wiley/crsRef/12645268
51. Adams RJ, Brambilla DJ, Granger S, Gallagher D, Vichinsky E, Abboud MR, et al. Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study. Blood 2004;103(10):3689-94. x-wiley/crsRef/12645259
52. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al. Risk of stroke in children with sickle cell disease and abnormal transcranial doppler ultrasound (TCD). Blood 1999;94(10 Suppl 1):419a. x-wiley/crsRef/12645260
53. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al. Stroke prevention in sickle cell disease (STOP): Baseline characteristics of trial patients. 22nd Annual Meeting of the National Sickle Cell Disease Program. 1997:41. x-wiley/crsRef/12645261
54. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al. Stroke prevention in sickle cell disease (STOP): final results. 25th Annual Meeting of the National Sickle Cell Disease Program. 2001. [Abstract no: #8]x-wiley/crsRef/12645263
55. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al. Stroke prevention in sickle cell disease (STOP): final results. Blood 2000;96(11 Pt 1):10a. x-wiley/crsRef/12645262
56. Adams RJ, Brambilla DJ, McKie V, Files B, Vichinsky E, Abboud M, et al. Stroke prevention in sickle cell disease (STOP): follow-up after closure of the trial. Blood 1998;92(10 Suppl 1):527a. x-wiley/crsRef/12645264
57. Adams RJ, Brambilla DJ, McKie VC, Files B, Vichinsky E, Abboud M, et al. Stroke prevention in sickle cell disease (STOP): baseline characteristics of trial patients. Blood 1997;90(10 Suppl 1):123a. x-wiley/crsRef/12645265
58. Adams RJ, Brambilla DJ, Vichinsky E, Abboud M, Pegelow C, Carl EM, et al. Risk of stroke and conversion to abnormal TCD in children screened with transcranial doppler (TCD) during the STOP study. National Sickle Cell Disease Program 30th Annual Meeting; 2002 Sept 17-21. 2002:3. x-wiley/crsRef/12645266
59. Adams RJ, Brambilla DJ, Vichinsky E, Abboud M, Pegelow C, Carl EM, et al. Stroke prevention trial in sickle cell anemia (STOP study): Risk of stroke in 1933 children screened with transcranial doppler (TCD). 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:54. x-wiley/crsRef/12645267
60. Adams RJ, Carl EM, McKie VC, Odo NA, Kutlar A, Phillips M, et al. A pilot trial of hydroxyurea to prevent strokes in children with sickle cell anemia. 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:53. x-wiley/crsRef/12645269
61. Adams RJ, Lackland DT, Brown L, Brown D, Voeks J, Fullerton HJ, et al. Transcranial Doppler Re-screening of Subjects who Participated in STOP and STOP. American journal of hematology 2016;91(12):1191-4. x-wiley/crsRef/12645270
62. Adams RJ, McKie V, Files B, Vichinsky E, Abboud M, Hsu L, et al. Stroke prevention in sickle cell disease (STOP): Results of transcranial doppler ultrasound screening stroke risk. Stroke 1998;29(1):308. x-wiley/crsRef/12645271
63. Adams RJ, McKie VC, Brambilla DJ, Carl E, Gallagher D, Nichols FT, et al. Stroke prevention trial in sickle cell anemia. Controlled Clinical Trials 1998;19(1):110-29. x-wiley/crsRef/12645272
64. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine 1998;339(1):5-11. [NCT00000592: Stroke Prevention in Sickle Cell Anemia (STOP 1)]x-wiley/crsRef/12645273
65. Anonymous. Transfusion to prevent first stroke in children with sickle cell anemia. Journal of the American Ostoepathic Association 1998;98(7):363-4. x-wiley/crsRef/12645275
66. Bulas DI, Jones A, Seibert JJ, Driscoll C, O'Donnell R, Adams RJ. Transcranial Doppler (TCD) screening for stroke prevention in sickle cell anemia: pitfalls in technique variation. Pediatric Radiology 2000;30(11):733-8. x-wiley/crsRef/12645276
67. Cohen AR. Sickle cell disease - new treatments, new questions. New England Journal of Medicine 1998;339(1):42-4. x-wiley/crsRef/12645277
68. Duncan GW. Ischemic stroke in sickle cell disease: a review. Tennessee Medicine 1997;90(12):498-9. x-wiley/crsRef/12645278
69. Files B, Brambilla D, Kutlar A, Miller S, Pegelow C, Vichinsky E, et al. A randomized trial of chronic transfusion to prevent stroke in sickle cell anemia: changes in ferritin with chronic transfusion. Blood 1998;92(10 Suppl 1):528a. x-wiley/crsRef/12645279
70. Files B, Brambilla D, Kutlar A, Miller S, Vichinsky E, Wang W, et al. Longitudinal changes in ferritin during chronic transfusion: a report from the Stroke Prevention Trial in Sickle Cell Anemia (STOP). Journal of Pediatric Hematology/Oncology 2002;24(4):284-90. x-wiley/crsRef/12645280
71. Gates A, Rogers MA, Puczynski M. Stroke prevention trial in sickle cell anemia: comments on effects of chronic transfusion on pain. Journal of Pediatrics 2002;141(5):742-3. x-wiley/crsRef/12645281
72. Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, et al. Alpha thalassemia is associated with decreased risk of abnormal transcranial doppler ultrasonography in children with sickle cell anemia. Journal of Pediatric Hematology/Oncology 2003;25(8):622-8. x-wiley/crsRef/12645282
73. Hyacinth HI, Gee BE, Voeks JH, Adams RJ, Hibbert J. High frequency of RBC transfusions in the STOP study was associated with reduction in serum biomarkers of neurodegeneration, vascular remodeling and inflammation. Blood. 2012; Vol. 120, issue 21. [Abstract no: 244; CENTRAL: 999896; CRS: 5500127000000021]x-wiley/crsRef/12645283
74. Kanter J, Kwiatkowski J, Fullerton HJ, Voeks J, Debenham E, Brown LJ, et al. Impact of TCD screening protocol on the incidence of hemorrhagic stroke in children and young adults with sickle cell disease. Blood 2015;126(23):3402. x-wiley/crsRef/12645284
75. Kutlar A, Brambilla D, Clair B, Haghighat A, Bakanay S, Adams G, et al. Candidate gene polymorphisms and their association with TCD velocities in children with sickle cell disease. Blood. 2007; Vol. 110, issue 11. [Abstract no: 429]x-wiley/crsRef/12645285
76. Kutlar A, Harbin J, Jackson B, Holley L, Gallagher D, Clair B, et al. Laboratory parameters in patients randomized in the STOP study and their modification by transfusion. Blood 2000;96(11 Pt 2):18b-9b. x-wiley/crsRef/12645286
77. Kutlar A, Harbin J, Jackson BB, Holley LGD, Clair B, Brambilla D, et al. Baseline laboratory parameters in patients randomized to the STOP study and their modification by transfusion. 24th Annual Meeting of the National Sickle Cell Disease Program. 2000:82a. x-wiley/crsRef/12645287
78. Kwiatkowski JL, Brambilla DJ, Granger S, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease. Blood. 2003; Vol. 102, issue 11. [Abstract no: 408]x-wiley/crsRef/12645288
79. Kwiatkowski JL, Granger S, Brambilla DJ, Brown RC, Miller ST, Adams RJ. Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial. British Journal of Haematology 2006;134(3):333-9. x-wiley/crsRef/12645289
80. Kwiatkowski JL, Kanter J, Fullerton HJ, Voeks J, Debenham E, Brown DG, et al. Ischemic stroke in children and young adults with sickle cell disease (SCD) in the post-stop era. Blood 2015;126(23):68. [CFGD Register: SC4fff, SC185q]x-wiley/crsRef/12645290
81. Kwiatkowski JL, Morales K, Brambilla DJ, Files B, Adamkiewicz T, Adams RJ. Long-term follow-up of transcranial doppler ultrasonography in children with sickle cell disease: Results of the STOP and STOP II patient cohorts. Blood 2002;100(11 Pt 1):663a. x-wiley/crsRef/12645291
82. Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood 2006;108(3):847-52. x-wiley/crsRef/12645292
83. Lee SB, Ramsingh D, Kutlar A, Holley L, McVie VC, Adams RJ. C-reactive protein in children with sickle cell disease at risk for stroke in the STOP study. Stroke 2002;33(1):373. x-wiley/crsRef/12645293
84. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 2006;37(6):1424-6. [CFGD Register: SC4uu]x-wiley/crsRef/12645294
85. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Transfusion lowers plasma-free hemoglobin in children with sickle cell disease at risk for stroke. Stroke 2006;37(2):695-6. [CFGD Register: SC4ggg]x-wiley/crsRef/12645295
86. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher C, et al. Impact of chronic transfusion on non-neurological events during the Stroke Prevention Trial in sickle cell anemia (STOP). Pediatric Research 2000;47(4 Pt 2):251A. x-wiley/crsRef/12645296
87. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher C, et al. Impact of chronic transfusion on non-neurological events during the stroke prevention trial in sickle cell anemia (TOP). 24th Annual Meeting of the National Sickle Cell Disease Program. 2000:61a. x-wiley/crsRef/12645297
88. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. Journal of Pediatrics 2001;139(6):785-9. x-wiley/crsRef/12645298
89. Nichols FT, Jones AM, Adams RJ. Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing. Journal of Neuroimaging 2001;11(4):354-62. x-wiley/crsRef/12645299
90. Olivieri N, Brambilla D, McKie V, Piomelli S, Kutlar A, Files B, et al. Changes in cerebral blood flow velocities during chronic transfusion therapy to prevent stroke in sickle cell disease. Blood 2000;96(11 Pt 1):486a. x-wiley/crsRef/12645300
91. Pegelow CH, Adams R, Hsu L, McKie V, Wang W, Zimmerman R, et al. Children with silent infarct and elevated transcranial doppler ultrasonography velocity are at increased risk of subsequent infarctive events. 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:137. x-wiley/crsRef/12645301
92. Pegelow CH, Wang W, Granger S, Hsu LL, Vichinsky E, Moser FG, et al. Silent infarcts in children with sickle cell anemia and abnormal cerebral artery velocity. Archives of Neurology 2001;58(12):2017-21. x-wiley/crsRef/12645302
93. Sarnaik SA. Prevention of stroke by transfusions in children with sickle cell anemia. New England journal of medicine 1998;339:1477-8. x-wiley/crsRef/12645303
94. Sayer G, Bowman L, Clair B, Cail A, Blanchard B, Natrajan K, et al. Long term outcome of patients enrolled into STOP and STOP II trials: a single center experience. Blood. 2012; Vol. 120, issue 21. [Abstract no: 3219; CENTRAL: 999895; CRS: 5500127000000020]x-wiley/crsRef/12645304
95. Styles L, De Jong K, Vichinsky E, Lubin B, Adams R, Kuypers F. Increased RBC phosphatidylserine exposure in sickle cell disease patients at risk for stroke by transcranial Doppler screening. Blood 1997;90(10 Suppl 1):604a-5a. x-wiley/crsRef/12645305
96. Vichinsky E, Luban E, Wright E, Olivieri N, Driscoll C, Pegelow C, et al. Prospective red cell phenotype matching in STOP - a multi-centre transfusion trial. 23rd Annual Meeting of the National Sickle Cell Disease Program. 1999:163. x-wiley/crsRef/12645306
97. Vichinsky E, Luban N, Wright E, Olivieri N, Driscoll C, Pegelow C, et al. Prospective red cell phenotype matching in STOP - a multi-center transfusion trial. Blood 1998;92(10 Suppl 1):528a. x-wiley/crsRef/12645307
98. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41(9):1086-92. x-wiley/crsRef/12645308
99. Wang W, Morales K, Olivieri N, Styles L, Scher C, Adams R, et al. Effect of chronic transfusion on growth in children with sickle cell anemia: results of the STOP trial. National Sickle Cell Disease Program 30th Annual Meeting Conference; 2002 Sept 17-21. 2002:100. x-wiley/crsRef/12645309
100. Wang WC, Morales KH, Scher CD, Styles L, Olivieri N, Adams R, et al. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. Journal of Pediatrics 2005;147(2):244-7. x-wiley/crsRef/12645310
101. Styles LA, Abboud M, Larkin S, Lo M, Kuyper FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. Proceedings of the 27th Annual Meeting of the National Sickle Cell Disease Program; 2004 Apr 18-21; Los Angeles. 2004:72. [CFGD Register: SC174a]x-wiley/crsRef/2843551
102. Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. British Journal of Haematology 2006;136(2):343-4. [CFGD Register: SC174b]x-wiley/crsRef/2843552
103. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. New England Journal of Medicine 1998;339(1):5-11.
104. Al Hajeri A, Serjeant GR, Fedorowicz Z. Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006957]
105. Alvim RC, Viana MB, Pires MA, Franklin HM, Paula MJ, Brito AC, et al. Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. Acta Haematologica 2005;113(4):228-33.
106. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 1998;92(9):3082-9.
107. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994;84(2):643-9.
108. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cocrane.org.
109. El-Hazmi M, Al-Fawaz I, Warsy A, Opawoye A, Taleb H, Howsawi Z, et al. Piracetam for the treatment of sickle cell disease in children - a double blind test. Saudi Medical Journal 1998;19(1):22-7.
110. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
111. Emre U, Miller ST, Gutierez M, Steiner P, Rao SP, Rao M. Effect of transfusion in acute chest syndrome of sickle cell disease. Journal of Pediatrics 1995;127(6):901-4.
112. Farooq S, Abu Omar M, Salzman GA. Acute chest syndrome in sickle cell disease. Hospital Practice 2018;46(3):144–51.
113. Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Reviews 1989;3(1):18-28.
114. Gladwin MT, Schechter AN, Shelhamer JH, Ognibene FP. The acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. American Journal of Respiratory and Critical Care Medicine 1999;159(5):1368-1376.
115. Golden C, Styles L, Vichinsky E. Acute chest syndrome and sickle cell disease. Current Opinion in Hematology 1998;5(2):89-92.
116. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
117. Higgins JPT, Altman DG, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
118. Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clinical Trials 2009;6(1):16-27.
119. Knight-Madden JM, Hambleton IR. Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 9. [DOI: 10.1002/14651858.CD003733]
120. Loureiro MM, Rozenfeld S. Epidemiology of sickle cell disease hospital admissions in Brazil. Revista de Saúde Pública 2005;39(6):943-9.
121. Martí-Carvajal AJ, Conterno LO, Knight-Madden JM. Antibiotics for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2019, Issue 9. [DOI: 10.1002/14651858.CD006110.pub2]
122. Njamnshi AK, Mbong EN, Wonkam A, Ongolo-Zogo P, Djientcheu VD, Sunjoh FL, et al. The epidemiology of stroke in sickle cell patients in Yaounde, Cameroon. Journal of Neurological Sciences 2006;250(1-2):79-84.
123. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2012;381(9861):142-51.
124. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
125. Sergeant GR. Natural history and determinants of clinical severity of sickle cell disease. Current Opinion in Hematology 1995;2(2):103-8.
126. Sterne J, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
127. Strouse JJ, Takemoto CM, Keefer JR, Kato GJ, Casella JF. Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease. Pediatric Blood Cancer 2008;50(5):1006-12.
128. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology / the Education Program of the American Society of Hematology 2006;2006(1):48-53.
129. Taylor C, Carter F, Poulose J, Rolle S, Babu S, Crichlow S. Clinical presentation of acute chest syndrome in sickle cell disease. Postgraduate Medical Journal 2004;80(944):346-9.
130. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997;89(5):1787-92.
131. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. New England Journal of Medicine 2000;342(25):1855-65.
132. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312(10):1033-48.
133. Zandian KM, Pedram M, Kiekhaie B, Valavi A, Kianpour Ghahfarokhi F. Assessing clinical laboratory funding of sickle cell disease and other associated disorders in Khuzestan province. Apadana Journal of Clinical Research 2012;1:21-5.
134. Alhashimi D, Fedorowicz Z, Alhashimi F, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007843.pub2]
135. Dastgiri S, Dolatkhah R. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2016, Issue 8. [DOI: 10.1002/14651858.CD007843.pub3]